Does disease activity at the start of biologic therapy influence health care costs in patients with RA?

Rheumatology
Kari JohanssonARTIS Study Group

Abstract

To investigate whether disease activity at baseline influences health care costs in patients with RA initiating biologic treatment. In the Swedish Biologics Register, we identified patients with RA with baseline 28-joint DAS (DAS28) recorded and starting their first biologic in 2007-11 [n = 1638 with moderate disease activity (DAS28 3.2-5.1) and n = 1870 with high disease activity (DAS28 > 5.1)]. Data on inpatient and outpatient care and prescription drugs were retrieved from nationwide registers. Mean cost differences were estimated adjusted for age, sex and costs the year before treatment start. Patients with high (vs moderate) disease activity were older (60 vs 56 years; P < 0.001), but did not differ in sex distribution (75 vs 74% women; P = 0.99) or disease duration (10 vs 10 years; P = 0.13). The year after initiation of biologics, patients with high (vs moderate) baseline disease activity accumulated 9% higher health care costs, but the difference was not statistically significant after adjustment [€19,333 vs €17,810; adjusted difference €870 (95% CI -2, 1742)]. In the subgroup of patients with up to 4 years of follow-up data, decreasing costs were observed over the follow-up time, but no difference was found between pat...Continue Reading

References

Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber
Jan 18, 2006·Annals of the Rheumatic Diseases·J AsklingL Klareskog
Aug 27, 2009·Rheumatology·Kimme L HyrichUNKNOWN British Society for Rheumatology Biologics Register
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Dec 15, 2010·Annals of the Rheumatic Diseases·Martin NeoviusUNKNOWN ARTIS study group
Nov 29, 2013·Annals of the Rheumatic Diseases·M NeoviusUNKNOWN ARTIS Study Group
Nov 8, 2014·Scandinavian Journal of Rheumatology·H WadströmJ Askling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.